|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500113587 |
|
最近更新日期: Date of Last Refreshed on: |
2025-12-01 11:19:27 |
|
注册时间: Date of Registration: |
2025-12-01 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
地氟烷与丙泊酚用于老年患者肩关节镜手术全身麻醉的比较:一项前瞻性随机研究 |
|
Public title: |
Comparison of Desflurane versus Propofol for general anesthesia in elderly frailty patients undergoing shoulder arthroscopic surgery: a prospective randomized study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
地氟烷与丙泊酚用于老年患者肩关节镜手术全身麻醉的比较:一项前瞻性随机研究 |
|
Scientific title: |
Comparison of Desflurane versus Propofol for general anesthesia in elderly frailty patients undergoing shoulder arthroscopic surgery: a prospective randomized study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李龙飞 |
研究负责人: |
张兵 |
|
Applicant: |
Li Longfei |
Study leader: |
Zhang Bing |
|
申请注册联系人电话: Applicant telephone: |
+86 156 0360 6337 |
研究负责人电话: Study leader's telephone: |
+86 451 8660 5029 |
|
申请注册联系人传真 : Applicant Fax: |
045186605452 |
研究负责人传真: Study leader's fax: |
045186605452 |
|
申请注册联系人电子邮件: Applicant E-mail: |
15603606377@163.com |
研究负责人电子邮件: Study leader's E-mail: |
zhang_bing08@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国黑龙江省哈尔滨市南岗区学府路246号 |
研究负责人通讯地址: |
中国黑龙江省哈尔滨市南岗区学府路246号 |
|
Applicant address: |
No. 246 Xuefu Road, Nangang District, Harbin, Heilongjiang, China |
Study leader's address: |
No. 246 Xuefu Road, Nangang District, Harbin, Heilongjiang, China |
|
申请注册联系人邮政编码: Applicant postcode: |
150000 |
研究负责人邮政编码: Study leader's postcode: |
150000 |
|
申请人所在单位: |
哈尔滨医科大学附属第二医院 |
||
|
Applicant's institution: |
The Second Affiliated Hospital of Harbin Medical University |
||
|
研究负责人所在单位: |
哈尔滨医科大学附属第二医院 |
||
|
Affiliation of the Leader: |
The Second Affiliated Hospital of Harbin Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KY2025-313号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
哈尔滨医科大学附属第二医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical ethics committee of the Second Affiliated Hospital of Harbin Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-10-15 00:00:00 |
||
|
伦理委员会联系人: |
田海 |
||
|
Contact Name of the ethic committee: |
Tian Hai |
||
|
伦理委员会联系地址: |
中国黑龙江省哈尔滨市南岗区学府路246号 |
||
|
Contact Address of the ethic committee: |
No. 246 Xuefu Road, Nangang District, Harbin, Heilongjiang, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 451 8660 5084 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
哈尔滨医科大学附属第二医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second Affiliated Hospital of Harbin Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国黑龙江省哈尔滨市南岗区学府路246号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 246 Xuefu Road, Nangang District, Harbin, Heilongjiang, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-funding |
||||||||||||||||||||||
|
Target disease: |
Postoperative Recovery |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
比较地氟烷与丙泊酚用于肩关节镜手术全麻时对血流动力学稳定性及围术期不良事件(包括低血压、心律失常与肺部并发症)的影响,评估老年衰弱患者的恢复质量。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aimed to compare the effects of desflurane and propofol in general anesthesia and incidence of peri-operative adverse events including hypotension, arrhythmia and pulmonary complications in frailty patients. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
地氟烷组患者将接受6%地氟烷吸入治疗,丙泊酚组患者在插管后静脉注射丙泊酚TCI,目标血药浓度为4μg/ml。两组均通过静脉输注瑞芬太尼0.1-0.2μg.kg-1.min-1,麻醉深度根据双频指数(BIS)40-60进行动态调整。术中血流动力学指标(心率、脉搏、呼吸频率、平均动脉压)及阿片类药物用量将在以下时间点记录:T0(麻醉诱导前)、T1(麻醉诱导后10分钟)、T2(切口处)、T3(手术开始后30分钟)、T4(手术结束时)、T5(转入术后监护室)、T6(术后监护室离院)、T7(术后24小时)和T8(术后72小时)。T0-T4期间需记录BIS值。动脉氧分压和二氧化碳分压将在T0-T5期间进行监测。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
Patients in desflurane group will receive a 6 VOL% desflurane inhalation, while patients in propofol group will be received an intravenous propofol TCI with the target blood concentration of 4μg/ml once the patient has been intubated. In both groups, remifentanil 0.1-0.2 μg.kg-1.min-1 will be intravenously infused, and the depth of anesthesia will be titrated according to the bispectral index (BIS) (40-60). Intraoperative hemodynamics (heart rate, SBP, DBP, mean blood pressure) and opioid dosage will be recorded at T0 (before anesthesia induction), T1 (10 minutes after anesthesia induction), T2 (at skin incision), T3 (30 minutes after surgery starts), T4 (at the end of surgery), T5 (entry into PACU), T6 (exit from PACU), T7 (24 hours after surgery), and T8 (72 hours after surgery). Record BIS value at T0-T4. Arterial oxygen pressure and carbon dioxide pressure will be assessed at T0-T5. |
||||||||||||||||||||||
|
纳入标准: |
1.女性或男性在 ICF 签署时年龄≥65 岁; 2. FFP≥3; 3. ASA I-III ; 4. 择期肩关节镜手术 ; 5. 预期手术时间<3h; 6. BMI 18-25 kg/m2; 7. 签署知情同意书 ; 8.小学以上学历。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. The age of the female or male at the time of ICF signing is >= 65 years old; 2. FFP >= 3; 3. ASA I-III; 4. Elective shoulder arthroscopic surgery; 5. The expected operation time is < 3 hours; 6. BMI 18 - 25 kg/m2; 7. Signed the informed consent form; 8. Has a high school education or above. |
||||||||||||||||||||||
|
排除标准: |
1. 不能合作的精神疾病患者; 2. 有焦虑或抑郁或认知障碍的个体,术前蒙特利尔认知评估(MoCA)评分< 26; 3. 谵妄病史; 4. 严重的心血管/肝脏/肾脏疾病; 5. 有麻药过敏史或禁忌症; 6. 最近 90 天内有慢性阿片类药物或苯二氮?类药物滥用史或慢性酒精滥用史; 7. 凝血功能异常; 8. 急诊手术; 9. 不能获得知情同意; 10. 拒绝手术; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with mental disorders who cannot cooperate; 2. Individuals with anxiety, depression or cognitive impairments, with a preoperative Montreal Cognitive Assessment (MoCA) score of less than 26; 3. History of delirium; 4. Severe cardiovascular/liver/kidney diseases; 5. History of drug allergy or contraindication to anesthesia; 6. History of chronic opioid or benzodiazepine abuse or chronic alcohol abuse within the last 90 days; 7. Abnormal coagulation function; 8. Emergency surgery; 9. Unable to obtain informed consent; 10. Refuses surgery; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-01 00:00:00至 To 2028-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-01-01 00:00:00 至 To 2028-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
研究人员将采用计算机生成的随机分组算法,按1:1比例将患者随机分配至地氟烷麻醉组或丙泊酚麻醉组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Patients will be randomly assigned to desflurane-based or propofol-based anesthesia using a computer-generated permuted block randomization sequence with 1:1 ratio. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
本研究在静脉麻醉与吸入麻醉的实施方面将采用单盲设计。然而,针对衰弱患者术后不良事件(包括低血压、心律失常和肺部并发症)的发生情况,将由两类研究者共同完成:一名麻醉医师仅负责全身麻醉实施,另一名评估医师则不知晓随机分组情况,但需了解具体治疗方案以进行评估工作。 |
|
Blinding: |
Study will be performed single-blind in terms of intravenous and inhalational anesthesia. However, the incidence of postoperative adverse events including hypotension, arrhythmia and pulmonary complications in frailty patients will be conducted by two investigator types: one anesthesiologist will only perform the general anesthesia, and the other will perform the assessment who is blinded to the randomization and will be, therefore, necessarily unblinded to the treatment conditions. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究的数据收集和管理将分为两个主要部分:病例记录表(CRF)的使用和电子数据采集(EDC)系统,其中ResMan被用作EDC系统。 病例记录表 设计和内容:CRF的设计将全面收集所有必要的研究数据,包括患者人口统计、治疗细节、临床反应和任何不良事件。CRF的设计将在研究开始前完成,以确保涵盖所有研究要求。 培训:在研究开始之前,所有参与数据收集的人员都将接受关于如何准确填写CRF的专业培训,以确保数据的一致性和准确性。 数据输入和验证:CRF中收集的数据将准确地输入电子数据采集和管理系统(EDC)。输入的数据将定期进行交叉验证,以确保其准确性。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data Collection and Management The data collection and management for this study will be divided into two main parts: the use of Case Record Forms (CRF) and an Electronic Data Capture (EDC) system, with ResMan being utilized as the EDC system. Case Record Form (CRF) Design and Content: The CRF will be designed to comprehensively collect all necessary study data, including patient demographics, treatment details, clinical responses, and any adverse events. The design of the CRF will be finalized before the start of the study to ensure all research requirements are covered. Training: Prior to the commencement of the study, all personnel involved in data collection will undergo specialized training on how to accurately fill in the CRF to ensure the consistency and accuracy of data. Data Entry and Verification: Data collected in the CRF will be accurately entered into the Electronic Data Capture and Management System (EDC). Entered data will be regularly cross-verified to ensure its correctness. Electronic Data Capture and Management System (EDC) - ResMan System Selection: ResMan has been chosen as the EDC system for this study. It is an internet-based EDC system that supports efficient, real-time data collection, management, and monitoring. System Configuration: Based on the specific needs of this study, ResMan will be customized, including setting up specific data entry interfaces, managing user permissions, and configuring data validation rules. Data Security and Protection: High-standard data security measures will be implemented to protect participant information and research data. This includes the use of encryption technologies, setting access controls, and conducting regular system security audits. Data Monitoring and Quality Control: Real-time data monitoring will be conducted through the ResMan system to promptly identify and correct any data entry errors or omissions. Additionally, regular data quality control checks will be conducted to ensure the integrity and accuracy of the data set. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |